VERNON HILLS, Ill.–(BUSINESS WIRE)–Feb. 18, 2005–Applied NeuroSolutions (OTCBB:APNS) (www.appliedneurosolutions.com), headquartered here, said today it was pleased to learn the Johns Hopkins Memory Bulletin has commented on advances being made by APNS in the field of Alzheimer’s disease diagnosis in an article entitled “A Spinal Fluid Test For Predicting AD” in its current issue.
“Word is beginning to get out about the progress Applied NeuroSolutions is making and, more broadly, about the significance of bringing next generation biological testing to the task of diagnosing Alzheimer’s disease” Dr. John DeBernardis, President and CEO, said. “As the technology leader in this emerging field, we are encouraged by the interest of the scientific community and the media.”
Applied NeuroSolutions, in cooperation with major universities in the Unites States and Europe, has run more than 2500 preclinical cerebrospinal (“CSF”) samples with an 85 percent-95 percent sensitivity and specificity.
Dr. DeBernardis said that APNS was working closely with the FDA to develop a pathway to bring this CSF test to market, and characterized the attitude of the FDA as “constructive and very supportive.”
APNS also announced in December 2004 it signed a non-exclusive agreement with bioMerieux, S.A. (Euronext : FR0010096479 – BIM) with the aim of bringing to market on a worldwide basis what is expected to be the first definitive biologic test for the diagnosis of AD.
“We encourage interested parties to take a look at this brief article, as well as the numerous peer reviewed publications on our website. We thank Johns Hopkins for their interest in our technology,” Dr. DeBernardis said.
The Memory Bulletin is a quarterly publication of John Hopkins University that gathers the most current information on preserving memory and coping with Alzheimer’s disease and other forms of memory loss at every stage.
Over the past decade, Applied NeuroSolutions has worked in cooperation with the Albert Einstein College of Medicine to develop a cerebrospinal fluid (CSF) assay that has consistently identified AD with much greater than 80% sensitivity and specificity in more than 2500 patient samples. This is the level of sensitivity and specificity that has been determined by the Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association to be the “industry standard” for AD diagnostics. In addition, the company is developing a blood serum test that would be sensitive and specific enough to also meet this “industry standard.”
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital.
For further information, please visit the company’s website at www.appliedneurosolutions.com, and review the company’s filings with the Securities and Exchange Commission.